Voyager Therapeutics Priced, Nasdaq: VYGR

Gene therapy biotech targeting Parkinson's disease and other CNS disorders.

Industry: Health Care

Latest Trade: $17.50 0.00 (0.0%)

First Day Return: +26.8%

Return from IPO: +25.0%

Industry: Health Care

We are a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system, or CNS. We focus on CNS diseases where we believe an adeno-associated virus gene, or AAV, therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. We have created a product engine, which enables us to engineer, optimize, manufacture and deliver our AAV-based gene therapies that have the potential to provide durable efficacy following a single administration directly to the CNS. Our product engine has rapidly generated programs for five CNS indications, including advanced Parkinson's disease; a monogenic form of ALS; Friedreich's ataxia; Huntington's disease; and SMA. Our most advanced clinical candidate, VY-AADC01, is being evaluated for the treatment of advanced Parkinson's disease in an open-label, Phase 1b clinical trial with the goal of generating human proof-of-concept data in the second half of 2016. Our goal is to submit an IND for one of our current preclinical programs in 2017.
more less
IPO News for Voyager Therapeutics
more
IPO Data
IPO File Date 10/09/2015
Offer Price $14.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.0
Deal Size ($mm) $70
IPO Data
IPO Date 11/10/2015
Offer Price $14.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.0
Deal Size ($mm) $70
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2013
Employees 48
Website www.voyagertherapeutics.com